Skip to content

US Rep.’s fishy bet on this stock surges almost 60% in 2 months

US Rep.'s fishy bet on this stock surges almost 60% in 2 months

Finbold shone a spotlight on Wednesday, December 6, on an investment move by US Representative Josh Gottheimer that has raised some eyebrows due to its uncanny timing.

As per data from the trading data platform Quiver Quantitative, Gottheimer executed an “almost perfectly timed” stock trades involving Dutch payments company Adyen.

Remarkably, the congressman, a member of the House Financial Services Committee, divested Adyen’s shares in July, just a month before the company experienced its slowest revenue growth on record, leading to a drastic 50% stock plunge. 

The timing of these trades, given his legislative role and the company’s financial downturn, has prompted scrutiny over the potential conflict of interest and insider trading concerns.

In a strategic reversal, Gottheimer reinvested in Adyen in the subsequent months. This move coincided with a rebound in the company’s stock, highlighting the congressman’s investment acumen – or sheer luck. Adyen’s shares have since posted double-digit gains, reflecting a strong recovery.

Adyen’s OTC shares pop 58% since Gottheimer’s new investment

In its initial post involving Gottheimer’s bet on Adyen, Quiver Quantitative said that after selling the stock in July prior to its sharp decline, the US representative reinvested in the company’s shares on August 21. 

Since then, the company’s stock surged roughly 40%, delivering lucrative returns to the politician. 

In a new update on December 6, Quiver revealed that US representative Josh Gottheimer made an additional purchase of Adyen’s shares on October 16. In less than two months since this latest transaction, the Dutch payments company’s over-the-counter (OTC) shares have witnessed an impressive surge, soaring by over 58% – from approximately $7.6 to well over $12.2 – according to Google Finance data.

Adyen 6-month chart. Source: Google

The trade gains further intrigue given Adyen’s status as a financial services company and Gottheimer’s role as a member of the House Financial Services Committee. 

Despite Adyen being a non-US entity, the noteworthy connection underscores the nuanced interplay between a global financial player and a key legislative figure, prompting scrutiny of the potential implications of this relationship.

Buy stocks now with Interactive Brokers – the most advanced investment platform


Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Services

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.